The team’s central concern was the formation of disinfection by-products. Chlorination remains the most common disinfection method worldwide because it is cheap, simple, and provides a lasting protective residual, but chlorine reacts vigorously with the dissolved organic matter that hospital effluents contain in abundance. These reactions generate organic acids, aldehydes, and trihalomethanes, compounds with documented risks to aquatic ecosystems and human health. Peracetic acid, by contrast, is a broad-spectrum antimicrobial oxidant that decomposes into water and acetic acid, by-products considered harmless to aquatic life. Its global market is projected to grow faster than any other water treatment disinfectant, and the study set out to test whether that enthusiasm is scientifically justified when pharmaceuticals such as antibiotics are present in the water.

To answer the question under controlled and reproducible conditions, the researchers prepared a synthetic hospital wastewater based on a published formulation containing carbohydrates, proteins, salts, and organic matter at concentrations resembling real hospital discharges. The mixture included glucose, sodium carbonate, ammonium sulfate, potassium phosphate, and trace metals, and yielded an average chemical oxygen demand of roughly 1044 milligrams per liter and a pH of about 9.38, values consistent with published characterizations of actual hospital effluents from Brazil, China, India, Iran, Turkey, Benin, and Vietnam. The team then inoculated the synthetic effluent with Escherichia coli at approximately 10^5 colony-forming units per milliliter, a level reported in real hospital wastewater, using the standard ATCC 25922 reference strain as an indicator organism.

The experimental design was deliberately rigorous. A full factorial experiment crossed two disinfectants, the presence or absence of the antibiotic amoxicillin, two disinfectant concentrations of 5 and 15 milligrams per liter, and two contact times of 5 and 15 minutes, producing sixteen treatments that were each run in triplicate for a total of 48 samples. Amoxicillin was selected because of its widespread clinical use and frequent detection in hospital effluents, and was added at 23.58 milligrams per liter to match concentrations measured in real wastewater by other researchers. Statistical analysis using one-way ANOVA followed by Tukey’s post hoc tests identified significant differences among treatments for chemical oxygen demand, pH, residual disinfectant concentrations, and bacterial removal efficiency.

The microbiological results were strikingly clear: both disinfectants substantially reduced E. coli across all conditions, and the highest doses delivered reductions exceeding four logarithmic units, equivalent to inactivating more than 99.99 percent of the bacteria. The single best performance came from sodium hypochlorite at 15 milligrams per liter over 15 minutes, which achieved a 5.28 log reduction with a calculated C·t value of 48.30 milligram-minutes per liter. Peracetic acid at the same dose achieved reductions of 5.15 and 4.73 logs. Even the weakest treatments, peracetic acid at 5 milligrams per liter, delivered reductions approaching three logs. These findings align with earlier work showing that peracetic acid can match or exceed chlorine in inactivating E. coli, coliphages, and Clostridium perfringens in water with high organic content, and even methicillin-resistant Staphylococcus aureus in hospital surface disinfection studies.

The chemistry told a more nuanced story. Every treatment produced a measurable rise in chemical oxygen demand relative to the raw effluent, because both oxidants convert recalcitrant organic compounds into more biodegradable forms that still register in the COD assay. Notably, samples containing amoxicillin consistently showed higher COD values than their drug-free counterparts, and the largest increase, reaching 1066.5 milligrams per liter, occurred when amoxicillin-laced effluent was treated with 15 milligrams per liter sodium hypochlorite for 15 minutes. This suggests that even a single antibiotic can measurably alter the behavior and by-product profile of disinfection, a factor that most treatment studies do not account for. All treatments also lowered the pH of the alkaline synthetic effluent, with the largest drops observed in the highest-dose chlorination runs, a pattern consistent with the known tendency of trihalomethane formation to increase at elevated pH.

Residual chemistry raised additional red flags for chlorine. Treatments using 15 milligrams per liter of sodium hypochlorite left total and free residual chlorine concentrations exceeding the 2 milligrams per liter discharge limit enforced by the local sanitation utility, and above the free chlorine range of 0.09 to 0.55 milligrams per liter measured in real hospital effluents by earlier investigators. Residual chlorine is toxic to aquatic organisms and can select for chlorine-resistant bacteria and propagate antibiotic resistance genes in downstream treatment plants. The researchers specifically tested for chloroform, the dominant trihalomethane typically produced during chlorination, in two high-dose samples, but concentrations fell below the analytical quantification limit of 0.005 milligrams per liter. The authors caution, however, that their synthetic matrix lacks the recalcitrant compounds found in real hospital effluent, where chlorination can generate haloacetic acids, haloacetonitriles, haloketones, trichloronitromethane, and chloral hydrate.

Peracetic acid residuals behaved predictably, with higher doses leaving higher residuals, and organic matter consuming much of the disinfectant within the first five minutes of contact, echoing prior observations that organic compounds demand peracetic acid rapidly while inorganic constituents such as iron consume it more slowly over about an hour. From an economic standpoint, the study notes that although peracetic acid has historically been more expensive than chlorine, its self-decomposing nature eliminates costly dechlorination steps, and its lower doses and shorter contact times can generate operational savings. The global peracetic acid market is projected to reach 1.3 billion dollars by 2026, with the wastewater segment growing at roughly eight percent annually, and combined peracetic acid followed by chlorine dosing has shown promise at full scale for facilities seeking better disinfection compliance.

The authors conclude that peracetic acid is a credible alternative to chlorination for hospital wastewater pre-treatment, offering comparable E. coli inactivation while producing by-products that do not harm the environment. They emphasize, however, that their work was conducted on synthetic effluent under controlled laboratory conditions, and that further studies using real hospital wastewater are needed to confirm the findings and fully characterize by-product formation. They also call for research into the toxic potential of hospital effluents, particularly in Brazil, where no specific legislation establishes discharge standards for hospital effluents entering public sanitary sewer systems. As concerns about antibiotic resistance and pharmaceutical pollution intensify worldwide, the humble choice of a disinfectant chemical may prove to be one of the most consequential decisions a hospital can make about its environmental footprint.

Subject of Research: Comparative evaluation of sodium hypochlorite and peracetic acid for disinfecting synthetic hospital wastewater and controlling disinfection by-products

Article Title: Evaluation of sodium hypochlorite and peracetic acid for disinfection of synthetic hospital wastewater

Article References: Koga, A., dos Santos, D. F., Martins, D. C. C., de Oliveira, L. T., de Abreu Filho, B. A., Benatti, C. T., & de Barros, M. A. S. D. (2026). Evaluation of sodium hypochlorite and peracetic acid for disinfection of synthetic hospital wastewater. Heliyon, 12(15), Article e45429. https://doi.org/10.1016/j.heliyon.2026.e45429

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45429

Keywords: hospital wastewater, disinfection, peracetic acid, sodium hypochlorite, E. coli, disinfection by-products, trihalomethanes, amoxicillin, chemical oxygen demand, antibiotic resistance, wastewater treatment, Heliyon

The experimental organism, Chlorella vulgaris, is a globally distributed unicellular green alga that sits near the base of aquatic food webs. Because it photosynthesizes, grows quickly and responds rapidly to chemical stress, it is one of the standard test organisms used in ecotoxicology to evaluate how contaminants affect primary producers. If algal growth falters, the consequences cascade upward: less energy captured from sunlight means less food for zooplankton, fish and everything that depends on them. That is why the fate of a single microalgal species matters enormously when regulators try to judge whether a chemical in the water is safe.

The researchers focused on two members of the β-lactam family, the most widely prescribed class of antibiotics in human and veterinary medicine. The first was amoxicillin, a penicillin-derivative consumed in enormous quantities worldwide and frequently detected in effluent from hospitals, livestock operations and municipal treatment plants. The second was aztreonam, a monobactam antibiotic prized for its activity against gram-negative bacteria. Both drugs reach surface waters after being excreted by patients or discarded improperly, since unused antibiotics flushed down drains largely pass through conventional wastewater treatment intact. A recent body of literature has flagged improper disposal of unused antibiotics as an overlooked driver of antimicrobial resistance, but the Tianjin team was interested in a different consequence: what these molecules do to organisms that are not their targets.

The second contaminant was silver nanoparticles, engineered particles of metallic silver measuring mere billionths of a meter across. Silver nanoparticles are among the most commercially successful nanomaterials on the planet, embedded in textiles, food packaging, cosmetics, medical devices and water filters because of their potent antibacterial properties. That same potency, however, extends to non-target organisms, and the particles are known to shed silver ions as they age in the environment. Previous studies have documented toxicity of silver nanoparticles to bacteria, algae, fish and invertebrates, yet most regulatory risk assessments still evaluate chemicals one at a time, an approach that grossly underestimates exposure when multiple contaminants co-occur, as they inevitably do in real receiving waters downstream of wastewater outfalls.

The experimental design was straightforward but rigorous. Cultures of Chlorella vulgaris were exposed for 96 hours to each of the three substances individually across a gradient of concentrations, and then to binary combinations of the antibiotics with the silver nanoparticles. Growth inhibition was used as the primary endpoint, summarized by the median effect concentration, the dose that reduces algal growth by half over the exposure period. The ranking that emerged was unambiguous: silver nanoparticles were the most toxic of the three, aztreonam came second, and amoxicillin was the least harmful on its own. In every case, higher exposure concentrations produced progressively greater suppression of algal growth, confirming dose-dependent toxicity for each compound.

The crucial finding came from the cotreatments. When the antibiotics and silver nanoparticles were present together, their combined effect on the algae was synergistic, meaning the observed toxicity exceeded what would be predicted by simply adding the effects of each chemical alone. The nanoparticles did not merely contribute an independent share of damage; they actively magnified the harm caused by the antibiotics, and the antibiotics in turn intensified the damage caused by the nanoparticles. This kind of interaction is precisely what conventional single-substance testing misses, and it suggests that environmental concentrations of these pollutants, even when each falls below a formal toxicity threshold individually, could still endanger photosynthetic organisms in combination.

To understand what the synergy was doing at the cellular level, the team turned to scanning electron microscopy. The images told a stark story. Algae that had been exposed to a single contaminant showed visible but comparatively limited damage to their cell surfaces, while cells subjected to coexposure displayed markedly more severe structural disruption. The cell wall and membrane, the alga’s first lines of defense, appear to be a shared point of attack: β-lactam antibiotics interfere with cell wall integrity in bacteria, and silver nanoparticles are notorious for compromising membranes and generating reactive oxygen species. When both stressors arrive together, the cell’s protective architecture may be weakened from two directions at once, allowing each toxicant to penetrate more deeply and inflict more damage than either could alone.

Oxidative stress is likely a central player in this interaction. Aquatic toxicologists have long observed that antibiotics such as clarithromycin, erythromycin and roxithromycin trigger antioxidant responses in freshwater microalgae, forcing cells to divert resources into defensive enzymes at the expense of growth. Silver nanoparticles act through a complementary mechanism, releasing silver ions that disrupt electron transport and catalyze the formation of superoxide and other reactive oxygen species inside the cell. When both classes of compounds are present, the combined oxidative burden can overwhelm the antioxidant system, damaging photosynthetic machinery and lipids faster than the cell can repair them. The result is the synergy recorded in the growth data: a whole-cell collapse that neither contaminant could achieve independently at the same doses.

To make sense of the many physiological indicators measured across the study, the researchers applied grey correlation analysis, a statistical technique well suited to small datasets with uncertain or incomplete information. The method quantifies how strongly each measured parameter tracks with the overall toxic outcome, helping to identify which physiological responses are the best predictors of harm under combined exposure. By linking growth inhibition, ultrastructural damage and the underlying biochemical indicators within a single analytical framework, the analysis strengthens the mechanistic interpretation of the synergy and offers a template that other laboratories can use to disentangle complex, multi-stressor toxicity.

The wider implications reach well beyond one species of green alga. Antimicrobial resistance researchers have warned for years that antibiotics polluting aquatic environments do not simply disappear; they persist, transform and interact with other contaminants, including the engineered nanomaterials that society is releasing in ever-larger quantities. This study adds a critical ecological dimension to that concern, showing that the coexistence of β-lactam antibiotics and silver nanoparticles in water is not merely a matter of two pollutants sharing space but of chemically interactive stressors whose joint toxicity to primary producers is greater than their parts. The authors argue that their findings contribute substantially to understanding the joint effects of these contaminants on aquatic organisms and provide solid evidence for the ecological risk assessment of their coexistence in natural waters. For regulators, the message is sobering: risk assessments that test chemicals in isolation will systematically understate the threat, and future water-quality standards may need to account explicitly for mixtures of antibiotics and nanomaterials. For the rest of the ecosystem, the study is a reminder that the health of entire food webs can hinge on the microscopic cells that convert sunlight into life, and that those cells are quietly registering the cumulative burden of everything humanity sends downstream.

Subject of Research: Combined toxicity of β-lactam antibiotics and silver nanoparticles to the freshwater microalga Chlorella vulgaris

Article Title: Physiological responses of Chlorella vulgaris upon coexposure to β-lactam antibiotics and Ag NPs

Article References: Lu, X., Zhang, Z., Huang, R., & Ge, Y. (2026). Physiological responses of Chlorella vulgaris upon coexposure to β-lactam antibiotics and Ag NPs. Ecotoxicology, 35(7), Article 163. https://doi.org/10.1007/s10646-026-03150-4

Image Credits: AI Generated

DOI: 10.1007/s10646-026-03150-4

Keywords: silver nanoparticles, β-lactam antibiotics, amoxicillin, aztreonam, Chlorella vulgaris, combined toxicity, synergistic effects, ecotoxicology, freshwater algae, oxidative stress, ecological risk assessment, water pollution

The heart of the technology is deceptively small: spherical nanoparticles roughly 30 nanometers across, each built around a core of iron oxide wrapped in a protective silica shell. This architecture gives the particles two crucial properties at once. The iron oxide core makes them strongly magnetic, allowing them to be maneuvered and concentrated within a sample without the lengthy centrifugation steps that conventional immunoassays demand, while the silica shell provides a chemically stable surface onto which the researchers attach thousands of molecular structures that mimic the antigenic determinants of beta-lactam antibiotics. Ezequiel Pérez-Inestrosa, Professor of Organic Chemistry at the University of Malaga and one of the study’s authors, describes each particle as acting ‘like a tiny magnet covered with thousands of molecular hooks.’ If a patient’s blood contains IgE antibodies responsible for the allergy, those antibodies are captured far more readily than with existing methods.

The significance of that capture efficiency becomes clear when the immunology of drug allergy is considered. IgE antibodies are extraordinarily scarce in the bloodstream, and the allergic response to penicillins is directed against haptens, small chemical fragments that only become immunologically visible when they are covalently bound to carrier proteins in the body. Recreating these hapten-carrier complexes faithfully on a solid support is a formidable synthetic chemistry challenge, and it is precisely where the Malaga team’s organic chemistry expertise proves decisive. By presenting a dense, well-defined array of antibiotic-derived structures on the nanoparticle surface, the platform maximizes the probability that even low-abundance, clinically relevant IgE molecules will bind, and the magnetic separation then allows those bound antibodies to be isolated and measured cleanly against a low background of noise.

Performance in the laboratory translated directly into diagnostic accuracy. In the study, the researchers analyzed blood samples from nearly one hundred people: 50 patients with confirmed amoxicillin allergy and 44 individuals who tolerated these antibiotics without incident. The system detected virtually all true cases of allergy while substantially reducing both false negatives and false positives, according to María José Torres, Professor of Medicine and one of the study’s lead researchers. The platform was benchmarked against two established techniques, ImmunoCAP, the most widely used commercial test, and the conventional radioallergosorbent test known as RAST. The gap in sensitivity, particularly for amoxicillin, was stark. Where the nanoparticle platform flagged 98 percent of confirmed allergic patients, ImmunoCAP managed only around 17 percent, a shortfall that means the majority of genuinely allergic individuals have historically received negative results that offer false reassurance.

The stakes of getting these diagnoses right are far higher than they might first appear. Penicillin allergy is dramatically overdiagnosed. Although between 8 and 25 percent of the population report being allergic to these antibiotics, only between 1 and 10 percent actually are. That gap between perception and reality leaves millions of people carrying an incorrect label in their medical records, and the consequences cascade through their subsequent care. Patients mislabeled as penicillin-allergic are treated with alternative drugs that are generally less effective and more toxic, and the substitution contributes to the emergence of bacterial resistance, one of the most pressing threats in modern medicine. ‘This incorrect label leads to the use of alternative drugs that are generally less effective, more toxic and contribute to the emergence of bacterial resistance,’ Pérez-Inestrosa explains. He stresses that identifying these cases safely would make it possible to remove thousands of incorrect diagnoses that currently shape and constrain patients’ treatment.

Beyond accuracy, the new platform promises to make the diagnostic journey itself safer and simpler. The definitive test for drug allergy has long been the drug provocation test, in which the patient is deliberately given the suspected medication under close medical supervision. It is informative, but it carries genuine risks, including the possibility of triggering a severe systemic reaction, and it requires specialist settings and considerable time. The nanoparticle-based assay, by contrast, can be performed rapidly in the laboratory on a simple blood sample, without exposing the patient to the drug at all and without the lengthy centrifugation procedures that slow down conventional workflows. A reliable in vitro alternative of this kind could allow clinicians to triage patients efficiently, reserving provocation testing only for cases where it is truly necessary.

The study is also a showcase for collaborative, translational science. Alongside the University of Malaga’s Department of Organic Chemistry, where Yolanda Vida and María I. Montañez serve as the study’s lead authors, the work drew on the IBIMA BIONAD Platform, the Inflammatory Diseases Network (REI) and the Regional University Hospital of Malaga, combining synthetic chemistry, materials science, immunology and clinical allergy expertise in a single program. That breadth matters, because a diagnostic technology that lives or dies on the precision of surface chemistry must ultimately prove itself against the messy, variable reality of patient sera, and few single laboratories possess the full range of skills needed to close that loop.

The implications, if the technology survives the scrutiny that now follows, extend beyond the penicillins. Beta-lactams are the world’s most prescribed class of antibiotics, and reliable, rapid allergy diagnosis would unlock first-line therapy for the vast majority of people currently denied it. There are also immediate operational benefits: shorter laboratory turnaround, reduced reliance on radioisotope-based legacy assays such as RAST, and the potential for standardization across centers because the magnetic separation is straightforward to automate. The authors themselves, however, are careful about the pace of translation. In light of their findings, they emphasize the need for further, larger multicentre studies and formal clinical validation before the platform can be introduced into hospitals and used routinely, a prudent stance given that diagnostic tests must perform consistently across diverse populations and instrumentation.

Still, the trajectory of this work is a reminder of how materials science quietly reshapes clinical medicine. Thirty-nanometer spheres of iron oxide and silica, decorated with molecular hooks synthesized by organic chemists, have turned a notoriously unreliable diagnostic corner into something that approaches certainty. For the millions of patients whose misplaced allergy label steers them toward inferior antibiotics, and for the clinicians trying to reconcile a 98 percent sensitivity figure with the 17 percent of the status quo, that tiny magnetic scaffold may prove to be one of the most consequential pieces of chemistry in the allergy clinic in years. The University of Malaga team’s findings, published in Materials Today Bio, mark the point at which magnetic nanoparticles moved from the bench toward a clinically relevant role in the diagnosis of beta-lactam allergy.

Subject of Research: Magnetic nanoparticle-based in vitro diagnosis of allergy to beta-lactam antibiotics such as amoxicillin and other penicillins

Article Title: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins

Article References: Uma scientists develop a new technology that improves the diagnosis of allergy to antibiotics such as amoxicillin and other penicillins. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: magnetic nanoparticles, penicillin allergy, amoxicillin, beta-lactam antibiotics, IgE antibodies, in vitro diagnostics, ImmunoCAP, drug provocation test, antibiotic resistance, University of Malaga, Materials Today Bio, allergy diagnosis

Helicobacter pylori remains one of the most consequential human pathogens on the planet, colonizing the gastric mucosa of roughly half the world’s population and serving as the dominant risk factor for peptic ulcer disease, chronic gastritis, and gastric adenocarcinoma. Eradicating the bacterium has become progressively harder over the past two decades as clarithromycin and levofloxacin resistance has spread, pushing clinicians toward bismuth quadruple therapy and, more recently, toward dual therapies that pair a potent acid suppressant with high-dose amoxicillin. The logic of these dual regimens is elegant: by driving intragastric pH sharply upward, the acid blocker undermines H. pylori’s ecological niche and enhances amoxicillin’s stability and activity against actively dividing bacteria, while restricting the antibiotic arsenal to a single agent helps preserve susceptibility of other organisms. The arrival of vonoprazan, which binds reversibly to the gastric H+/K+-ATPase at a potassium-binding site and achieves faster, stronger, and more sustained acid inhibition than classical proton pump inhibitors, has energized this strategy, but direct comparisons with optimized proton pump inhibitor dual regimens have remained limited, particularly regarding collateral effects on the gut microbiome.

To address that gap, the research team enrolled a total of 110 H. pylori-positive patients and non-randomly assigned them to one of two fourteen-day-style dual regimens. Fifty patients received the P-CAB regimen, consisting of vonoprazan 20 milligrams twice daily combined with amoxicillin 750 milligrams four times daily, while sixty patients received the PPI regimen, comprising esomeprazole 20 milligrams four times daily with the same amoxicillin dosing. Twenty-two H. pylori-negative individuals served as healthy controls for microbiota benchmarking. Eradication success was determined four weeks after completion of therapy using the 13C-urea breath test, a noninvasive assay that exploits the bacterium’s urease enzyme to detect active infection. The investigators also gathered fecal samples at three time points, baseline before treatment, roughly two weeks into the post-therapy window, and at week six, to characterize shifts in microbial diversity, community composition, and predicted functional pathways through 16S rRNA gene sequencing.

On the pharmacological front, the two acid suppressants differ in ways that matter clinically. Proton pump inhibitors such as esomeprazole are acid-activated prodrugs that require an acidic environment to engage the pump irreversibly, meaning their effect accumulates over several doses and is blunted in the very hypersecretory or proton-pump-dense patients who most need acid control. Vonoprazan, by contrast, is active at neutral pH, accumulates in parietal cells, and exerts dose-dependent, reversible inhibition that reaches near-anacidic gastric conditions within hours and persists through once- or twice-daily dosing. That kinetic advantage is thought to explain why vonoprazan-based dual therapy performs well even in regions with high amoxicillin resistance, since sustained acid suppression amplifies amoxicillin’s bactericidal window. The esomeprazole arm in this study used a four-times-daily schedule specifically to maximize acid suppression and keep the comparison fair against the twice-daily vonoprazan regimen.

The headline efficacy finding favored vonoprazan across every analysis population. The P-CAB group achieved an eradication rate of 97.73 percent in the per-protocol analysis, compared with 84.20 percent in the esomeprazole group, a difference that reached statistical significance at P equals 0.04. Although the intention-to-treat and modified intention-to-treat analyses showed the same directional advantage for the vonoprazan regimen, those comparisons did not cross the threshold of statistical significance, a nuance the authors attribute in part to the non-randomized design and the modest sample size. Still, a cure rate approaching 98 percent in patients who completed the prescribed course places the vonoprazan dual approach among the most effective antibiotic-sparing strategies reported, comfortably exceeding the 90 percent benchmark that international consensus guidelines set for first-line eradication therapy.

Equally important for practice, the safety and tolerability picture was essentially identical between arms. Adverse reactions, which in dual amoxicillin regimens typically include diarrhea, nausea, taste disturbances, rash, and abdominal discomfort, occurred at comparable frequencies in the two groups, and patient compliance did not differ significantly between the P-CAB and PPI regimens. Neither regimen caused treatment-related events severe enough to disrupt the comparison, suggesting that the pharmacological intensity of vonoprazan did not translate into a clinical tolerability penalty. For gastroenterologists weighing first-line options, this aligns the choice more squarely on efficacy grounds, since the operational burden of four-times-daily amoxicillin dosing applies to both regimens equally.

The microbiota component of the study adds a layer of ecological context that eradication trials rarely capture. Using 16S rRNA gene amplicon sequencing of the V3 and V4 hypervariable regions, the team quantified alpha diversity, assessed community structure with principal co-ordinates analysis, and predicted functional shifts against the Kyoto Encyclopedia of Genes and Genomes reference pathways. Both eradication regimens delivered a discernible shock to the gut ecosystem: microbial diversity declined after treatment, community composition shifted measurably away from baseline and from the healthy control profile, and predicted metabolic pathways were transiently perturbed. Importantly, these disturbances followed a recovery trajectory over the follow-up period, with communities migrating back toward their pretreatment configuration by week six.

The two regimens left subtly different ecological fingerprints. The early decline in microbial diversity was more pronounced in the vonoprazan group, an observation consistent with the deeper and more sustained acid suppression that P-CABs deliver, since gastric acid and its downstream influence on the entire intestinal milieu shape which microbes survive transit into the lower gut. Yet the vonoprazan group also showed a tendency toward faster restoration of functional pathway profiles, hinting that the compositional damage and the functional damage may recover on different clocks. Across both arms, the researchers documented an increase in potential pathogenic bacteria and a corresponding decrease in short-chain fatty acid-producing bacteria after treatment, a pattern that matters because short-chain fatty acids such as butyrate fuel colonocytes, maintain epithelial barrier integrity, and exert anti-inflammatory signaling throughout the body. The fact that these SCFA producers rebounded over the six-week window will reassure clinicians, though the study’s design cannot exclude longer-lasting effects in some individuals.

The authors caution, appropriately, that the study was non-randomized, single-center, and modest in size, so the eradication difference should be interpreted as hypothesis-confirming rather than definitive, and the microbiota findings describe short-term dynamics only. Even so, the report lands at a moment when clinicians worldwide are retooling first-line H. pylori strategies amid rising antibiotic resistance. Vonoprazan-based dual therapy is already endorsed by growing bodies of guideline literature as a first-line option, and this comparison provides practical reassurance on two fronts simultaneously: it beats an optimized esomeprazole dual regimen where it counts, achieving eradication close to the theoretical ceiling while matching that regimen on safety and adherence, and the collateral microbiota damage it inflicts appears to be transient and self-repairing. For a bacterium that infects billions and drives one of the world’s most common cancers, treatment strategies that maximize cure rates while minimizing ecological and resistance costs represent exactly the kind of progress the field has been seeking, and this study offers a candid, quantified look at both sides of that bargain.

Subject of Research: Comparative efficacy of vonoprazan-based versus esomeprazole-based dual therapy for Helicobacter pylori eradication and short-term gut microbiota changes

Article Title: Comparative effects of vonoprazan-based and esomeprazole-based dual therapy on Helicobacter pylori eradication and short-term gut microbiota changes

Article References: Liu, Y., Qian, X., Yao, J., Fei, C., Zhang, Z., & Jiang, Z. (2026). Comparative effects of vonoprazan-based and esomeprazole-based dual therapy on Helicobacter pylori eradication and short-term gut microbiota changes. Gut Pathogens. https://doi.org/10.1186/s13099-026-00867-9

Image Credits: AI Generated

DOI: 10.1186/s13099-026-00867-9

Keywords: Helicobacter pylori, vonoprazan, esomeprazole, dual therapy, eradication, gut microbiota, 16S rRNA sequencing, potassium-competitive acid blocker, proton pump inhibitor, short-chain fatty acids, amoxicillin, 13C-urea breath test